4.45% 0.0105

Calidi Biotherapeutics Inc (CLDI)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Calidi Biotherapeutics Inc

Healthcare (1117)

Biotechnology (624)

(858) 794-9600

4475 Executive Drive, Suite 200, San Diego

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CLDI's Discussions on Twitter

Compare CLDI vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CLDI Calidi Biotherapeutics Inc	0.2405	2.57M	0	-25.74M	-21.41M	-4.938
VRTX Vertex Pharmaceuticals Inc	433.53	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.09	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.05	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.56	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.57	35.01B	606.42M	-1.28B	-997.58M	-6.403

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-22	Eingeleitet	H.C. Wainwright	Buy
2023-10-09	Eingeleitet	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Compare CLDI vs VRTX, REGN, ARGX, ALNY, INSM

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK

Calidi Biotherapeutics to reduce board size as director term nears expiration By Investing.com - Investing.com Australia

Calidi Biotherapeutics (CLDI) Hinges on High-Stakes Q4 2026 IND Filing as Market Waits for Catalyst - Bitget

Calidi Biotherapeutics to reduce board size as director term nears expiration - Investing.com India

Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks

Allan Camaisa to Leave Calidi Board; Scott Leftwich Joins Audit Committee - TradingView

Director transition leads Calidi Biotherapeutics (CLDI) to cut board size to five - Stock Titan

Calidi tees up new cancer-virus data before planned 2026 IND filing - Stock Titan

CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Sahm

Calidi brings tumor-targeted immune therapy data to cancer meeting - Stock Titan

CLDI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Investor in Calidi Biotherapeutics (CLDI) discloses 0.3% stake - Stock Titan

VIX Spike: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn

Inflation Data: Is Calidi Biotherapeutics Inc forming a breakout pattern2026 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn

Calidi Biotherapeutics Reports 2025 Financial Results, Advances CLD-401 Clinical Development and Expands RedTail Platform Partnerships - Minichart

Calidi Biotherapeutics, Inc. 2025 Annual 10-K Report Highlights Equity, Warrants, and Financial Arrangements - Minichart

Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline - TipRanks

Calidi 2025 10-K: $20.24M operating loss, $20.06M net loss, $5.6M cash - TradingView

Calidi Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Calidi Biotherapeutics (CLDI) 10-K shows going-concern risk and early oncology pipeline - stocktitan.net

Calidi Biotherapeutics (NYSE: CLDI) reports 2025 loss and $5.6M cash - stocktitan.net

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - Bitget

Calidi Biotherapeutics released its financial results for the fourth quarter and full year of 2025, along with an update on its recent operational progress. - bitget.com

CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch - Intellectia AI

Market Pulse: Will Calidi Biotherapeutics Inc benefit from sector rotation2026 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn

Gap Down: Should I hold or sell Calidi Biotherapeutics Inc nowMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials - The Manila Times

Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval - TradingView

Calidi Biotherapeutics Announces Partnership with Avance - GlobeNewswire

CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill

Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN

Calidi Biotherapeutics prices $5.2M underwritten public offering - MSN

Big Picture: Can Calidi Biotherapeutics Inc keep up with sector leaders2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn

Portfolio Recap: How much upside does Calidi Biotherapeutics Inc have2026 Market Mood & AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing - Sahm

Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit - Intellectia AI

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - Bitget

How a tumor-targeting virus therapy earned FDA support on its production - Stock Titan

Calidi Biotherapeutics Announces Proposed Public Offering of Common Stock and Warrants to Fund Growth Initiatives 12 - Minichart

Calidi Biotherapeutics Completes Dilutive Public Equity Offering - TipRanks

Calidi Biotherapeutics announces underwritten public offering - Investing.com Nigeria

Calidi Biotherapeutics Raises $6.03 Million in Unit Offering; Adds Warrant Agent and Amends Legacy Warrants - TradingView

Calidi Biotherapeutics (NYSE: CLDI) closes $6M unit and warrant deal - Stock Titan

Portfolio Update: Is Calidi Biotherapeutics Inc a stock for growth or value investors2026 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn

CLDI PE Ratio & Valuation, Is CLDI Overvalued - Intellectia AI

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - Bitget

Calidi Biotherapeutics closes $6M public offering By Investing.com - Investing.com Canada

Calidi Biotherapeutics Announces Closing of $6.0 Million - GlobeNewswire

Calidi Biotherapeutics closes $6M public offering - Investing.com

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option - The Manila Times

Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CLDI